640 related articles for article (PubMed ID: 27548616)
1. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells.
Qin H; Edwards JP; Zaritskaya L; Gupta A; Mu CJ; Fry TJ; Hilbert DM; LaFleur DW
Mol Ther; 2019 Jul; 27(7):1262-1274. PubMed ID: 31043341
[TBL] [Abstract][Full Text] [Related]
3. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
Morgan MA; Kloos A; Lenz D; Kattre N; Nowak J; Bentele M; Keisker M; Dahlke J; Zimmermann K; Sauer M; Heuser M; Schambach A
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372571
[TBL] [Abstract][Full Text] [Related]
4. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
6. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.
Bôle-Richard E; Fredon M; Biichlé S; Anna F; Certoux JM; Renosi F; Tsé F; Molimard C; Valmary-Degano S; Jenvrin A; Warda W; Pallandre JR; Bonnefoy F; Poussard M; Deschamps M; Petrella T; Roumier C; Macintyre E; Féger F; Brissot E; Mohty M; HoWangYin KY; Langlade-Demoyen P; Loustau M; Caumartin J; Godet Y; Binda D; Pagadoy M; Deconinck E; Daguindau E; Saas P; Ferrand C; Angelot-Delettre F; Adotévi O; Garnache-Ottou F
Leukemia; 2020 Dec; 34(12):3228-3241. PubMed ID: 32111969
[TBL] [Abstract][Full Text] [Related]
7. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
Wang ZZ; Lu Y; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):192-197. PubMed ID: 32311887
[No Abstract] [Full Text] [Related]
8. A CD123-specific chimeric antigen receptor augments anti-acute myeloid leukemia activity of Vγ9Vδ2 T cells.
Zhang X; Ang WX; Du Z; Ng YY; Zha S; Chen C; Xiao L; Ng JY; Chng WJ; Wang S
Immunotherapy; 2022 Apr; 14(5):321-336. PubMed ID: 35152722
[No Abstract] [Full Text] [Related]
9. Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
Wang XY; Bian MR; Lin GQ; Yu L; Zhang YM; Wu DP
Eur J Haematol; 2024 Jan; 112(1):83-93. PubMed ID: 37712633
[TBL] [Abstract][Full Text] [Related]
10. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.
El Khawanky N; Hughes A; Yu W; Myburgh R; Matschulla T; Taromi S; Aumann K; Clarson J; Vinnakota JM; Shoumariyeh K; Miething C; Lopez AF; Brown MP; Duyster J; Hein L; Manz MG; Hughes TP; White DL; Yong ASM; Zeiser R
Nat Commun; 2021 Nov; 12(1):6436. PubMed ID: 34750374
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
Front Immunol; 2020; 11():539654. PubMed ID: 33281809
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
[TBL] [Abstract][Full Text] [Related]
13. Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models.
Mu-Mosley H; Ostermann L; Muftuoglu M; Vaidya A; Bonifant CL; Velasquez MP; Gottschalk S; Andreeff M
Front Immunol; 2022; 13():880108. PubMed ID: 35615350
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
Atilla PA; McKenna MK; Watanabe N; Mamonkin M; Brenner MK; Atilla E
Cytotherapy; 2022 Mar; 24(3):282-290. PubMed ID: 34955406
[TBL] [Abstract][Full Text] [Related]
15. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Singh N; Frey NV; Engels B; Barrett DM; Shestova O; Ravikumar P; Cummins KD; Lee YG; Pajarillo R; Chun I; Shyu A; Highfill SL; Price A; Zhao L; Peng L; Granda B; Ramones M; Lu XM; Christian DA; Perazzelli J; Lacey SF; Roy NH; Burkhardt JK; Colomb F; Damra M; Abdel-Mohsen M; Liu T; Liu D; Standley DM; Young RM; Brogdon JL; Grupp SA; June CH; Maude SL; Gill S; Ruella M
Nat Med; 2021 May; 27(5):842-850. PubMed ID: 33888899
[TBL] [Abstract][Full Text] [Related]
16. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
Front Immunol; 2022; 13():847008. PubMed ID: 35464442
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
Habibi-Anbouhi M; Kafi Z; Ghazizadeh L; Kharazi S; Behdani M; Faraji F; Shokrgozar MA
Iran J Allergy Asthma Immunol; 2019 Oct; 18(6):679-687. PubMed ID: 32245312
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.
Meyer JE; Loff S; Dietrich J; Spehr J; Jurado Jiménez G; von Bonin M; Ehninger G; Cartellieri M; Ehninger A
Oncoimmunology; 2021; 10(1):1945804. PubMed ID: 34290907
[TBL] [Abstract][Full Text] [Related]
19. CD123 CAR T cells for the treatment of myelodysplastic syndrome.
Stevens BM; Zhang W; Pollyea DA; Winters A; Gutman J; Smith C; Budde E; Forman SJ; Jordan CT; Purev E
Exp Hematol; 2019 Jun; 74():52-63.e3. PubMed ID: 31136781
[TBL] [Abstract][Full Text] [Related]
20. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
Baroni ML; Sanchez Martinez D; Gutierrez Aguera F; Roca Ho H; Castella M; Zanetti SR; Velasco Hernandez T; Diaz de la Guardia R; Castaño J; Anguita E; Vives S; Nomdedeu J; Lapillone H; Bras AE; van der Velden VHJ; Junca J; Marin P; Bataller A; Esteve J; Vick B; Jeremias I; Lopez A; Sorigue M; Bueno C; Menendez P
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32527933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]